Welcome to the California Cancer Registry
NAACCR 2007 Gold Certification

Web Query Tool

Web Query Tool

Generate customized maps and tables of California cancer incidence or mortality rates.

Quick Links for More Information on Meaningful Use



Meaningful Use 2: Cancer Reporting in California

The California Department of Public Health (CDPH) is coordinating all reporting for Meaningful Use (MU) for California. CDPH is utilizing a Health Information Exchange (HIE) Gateway to receive and process MU files.  For more information on the CDPH HIE Gateway, please go to http://hie.cdph.ca.gov.

To participate in MU2 for Cancer Reporting, Physician Offices (PO) must have successfully participated in MU1, cancer data must meet the HL7 Clinical Document Architecture (CDA) 2.0 standard, and messages must conform to the CDA implementation specifications found in the Implementation Guide for Ambulatory Healthcare Provider Reporting to Central Cancer Registries (PDF, 1.9 MB).  In addition, the technology used by the PO to generate the HL7 CDA .XML message has to be a federally certified 2014 Edition EHR technology.

There are four transmission options for submitting MU2 data for Cancer Reporting:

If you do not know your transport method, please ask your Information Technology representative or your Electronic Health Record vendor prior to enrolling to submit MU2 cancer data. 


Onboarding Process

Instructions for Enrolling in MU2 Cancer Reporting

Step 1: Register with the CDPH HIE Gateway

If you have already registered with the CDPH HIE Gateway, log in to your account at https://hiegateway.cdph.ca.gov, click on the My Submissions tab, then skip to Step 5, item 2. 

  1. Register at the CDPH HIE Gateway by “Creating a New Account” at: https://hiegateway.cdph.ca.gov/Account/Register.aspx
  2. You will receive an email from HIEHelp@cdph.ca.gov requesting confirmation of your registration.

Step 2: Confirm your Email Address and Registration

  1. Click on the link provided in the email you received from HIEHelp@cdph.ca.gov.  You will be taken to a web page with a link to Step 3.

Step 3: Complete your Contact Information

  1. Click the “Step 3: Fill in Contact Information” link.
  2. You will be taken to a HOME web page with a link under Step 3: Complete Contact Information that states “This is a required step prior to signing up with a program”.  Click this link.
  3. Complete the information and hit the “Submit” button.
  4. You will be taken back to the HOME web page to continue to Step 4.

Step 4: Complete your Submitter Organization Information

  1. On the HOME web page, under Step 4:  Complete Submitter Organization Information there will be a link that states “This is a required step prior to signing up with a program”.  Click this link.
  2. Complete the information and hit the “Submit” button.
  3. You will be taken back to the HOME web page to continue to Step 5.

Step 5: Enroll for Cancer Reporting

  1. On the HOME web page, under Step 5, Program Enrollment Status, click the “here” link to enroll for Cancer Reporting
  2. You will be taken to a “Manage Submissions” web page.  Click the “Enroll” button next to California Cancer Registry (CCR).
  3. You will be taken to a CCR Supplemental Data page.
  4. Complete the information and hit the “Submit” button.
  5. You will be taken back to the HOME web page.
  6. You will receive an email from HIEHelp@cdph.ca.gov confirming your enrollment for MU2 Cancer Reporting with instructions on how to submit test data for validation.

Step 6: Testing/Validation

  1. Follow the instructions provided in the email for submitting your cancer data.
  2. Your data submission will be tested for valid HL7 CDA .XML structure.
  3. If issues arise during the validation of the data, CCR staff will communicate with you via email or telephone.
  4. Once CCR verifies that the data is structurally valid, you will receive an email from CCR with instructions for Ongoing Data Submission. 

Step 7: Ongoing Data Submission

  1. You can begin ongoing data submission in compliance with MU2 for Cancer Reporting.  .

While actively engaged in steps 1 – 5 above, you will be receiving emails and possibly telephone calls from CDPH HIE and CCR.  You should maintain copies of these communications for EHR Incentive Program audit purposes.

If you have any questions regarding these processes, you can contact our office at MU2CCRHelp@ccr.ca.gov


MU2 Skin Cancer Reporting Requirements

Cancer Reporting Requirements:

Dermatologists are required by law to report all new cases of melanoma to their regional cancer registry.

Please Note:  This reporting requirement is separate from the Medicare Physician Quality Reporting System (PQRS), and is mandated by California Health and Safety Code, Section 103885 and California Code of Regulations, Section 2593. These laws require that all cases of melanoma be reported to CCR when diagnosed by a health care provider, laboratory, or hospital. Required reporting enables California to identify disease trends, track disease outbreaks, and aid in preventive measures.

To report new cases of melanoma use the following form:

Below are the MU2 requirements for skin cancers.   This information is in California’s Volume I., Section II.1.4 – II.1.4.1-II.1.4.2

Reportable Skin Cancers Include:

  • Skin cancers in the genital sites (any histology) (vagina (C52.9); clitoris (C51.2); labium (C51.0); vulva (C51.9); prepuce (C60.0); penis (C60.9) and scrotum (C63.2) are reportable.
  • Malignant tumors of the skin such as
    • adnexal carcinomas (e.g., carcinomas of the sweat gland,
    • sebaceous gland,
    • ceruminous gland, and hair follicle,
    • adenocarcinomas,
    • lymphomas,
    • melanomas including the following
      • Early melanoma insitu*
      • Evolving melanoma insitu*                        
    • sarcomas
    • Merkel cell tumors
    • Any carcinoma arising in a hemorrhoid is reportable since hemorrhoids arise in mucosa, not in the skin.

Non-Reportable to the Cancer Registry:

  • Basal cell carcinomas of the skin
  • Epithelial carcinomas of the skin
  • Papillary carcinomas of the skin
  • Squamous cell carcinomas of the skin
  • Early Melanoma 
  • Evolving Melanoma  

NOTE:  The term “insitumust be included in diagnosis in order for early and evolving melanoma insitu to be reportable



HIE Gateway Help

Cancer Specific Support

Steven Starr: Steven.Starr@cdph.ca.gov

Maggie Burgos: Maggie.Burgos@cdph.ca.gov